Polaris invests across healthtech, life sciences, and B2B software, with a long history of backing biotech companies through to IPO - including Alnylam Pharmaceuticals, which went public in 2004. The firm supports entrepreneurs from seed through growth stage.
$19B invested cumulatively across funds (not a current single fund figure) AUM79/100 Power Score™1996 FoundedBoston, MA